within Pharmacolibrary.Drugs.ATC.P;

model P01CD01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00011166666666666667,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0028,
    k12             = 13.3,
    k21             = 13.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01CD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Melarsoprol is an organoarsenic compound used in the treatment of human African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei. It is particularly used for late-stage disease with central nervous system involvement. Because of its severe toxicity, especially encephalopathy, melarsoprol is reserved for cases where less toxic alternatives are not effective or not available.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in patients with late-stage African trypanosomiasis (adults), after intravenous administration.</p><h4>References</h4><ol><li><p>Keiser, J, et al., &amp; Burri, C (2000). Investigations of the metabolites of the trypanocidal drug melarsoprol. <i>Clinical pharmacology and therapeutics</i> 67(5) 478–488. DOI:<a href=\"https://doi.org/10.1067/mcp.2000.105990\">10.1067/mcp.2000.105990</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10824626/\">https://pubmed.ncbi.nlm.nih.gov/10824626</a></p></li><li><p>Soignet, SL, et al., &amp; Warrell, RP (1999). Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. <i>Cancer chemotherapy and pharmacology</i> 44(5) 417–421. DOI:<a href=\"https://doi.org/10.1007/s002800050998\">10.1007/s002800050998</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10501916/\">https://pubmed.ncbi.nlm.nih.gov/10501916</a></p></li><li><p>Ben Zirar, S, et al., &amp; Gibaud, S (2008). Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 70(2) 649–656. DOI:<a href=\"https://doi.org/10.1016/j.ejpb.2008.05.012\">10.1016/j.ejpb.2008.05.012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18582565/\">https://pubmed.ncbi.nlm.nih.gov/18582565</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01CD01;
